Perspective

CAR T-cells therapy as a ray of hope for cancer treatment

Downloads

Chopra, H., Chopra, S., Arora, S., & Dhama, K. (2023). CAR T-cells therapy as a ray of hope for cancer treatment. Trends in Immunotherapy, 8(2). https://doi.org/10.24294/ti.v8.i2.2432

Authors

  • Hitesh Chopra
    Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, India
  • Shivani Chopra Department of Biosciences, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai 602105, India
  • Sonia Arora Chandigarh Group of Colleges Landran, Kharar 140307, India
  • Kuldeep Dhama Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly 243122, India

New hope for patients with specific blood malignancies has arisen with the emergence of chimeric antigen receptor (CAR) T-cell therapy as a revolutionary approach to cancer immunotherapy. This groundbreaking therapy modifies a patient’s immune system such that their own T cells can identify and destroy cancer-specific antigens by expressing CARs. Multiple myeloma, lymphomas, and leukemias are among the blood malignancies that have been treated with six CAR T-cell treatments that have been approved by the FDA since 2017. The treatment entails drawing T cells out of the patient’s blood, changing their genes to produce CARs, and then reintroducing these modified cells into the patient. The CAR T-cells have the ability to identify cancer cells, proliferate, and kill them once they enter the circulation. This might lead to long-term protection from the illness. Patients with blood malignancies who have relapsed or are resistant to previous treatments have shown encouraging results in clinical studies, with some patients even managing to achieve long-term remissions. Cytokine release syndrome and neurological toxicities are two of the many potential adverse effects of CAR T-cell treatment that must be carefully managed. The complicated production method and expensive treatment cost further restrict its broad availability. Research is ongoing with the goals of improving the safety profile, increasing the effectiveness, and expanding the applicability of CAR T-cell therapy to solid tumors.

Keywords:

CAR-T cancer solid tumors leukaemia

References

  1. CAR T Cells: Engineering Immune Cells to Treat Cancer-NCI. Available online: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells (accessed on 28 May 2024).
  2. Sheykhhasan M, Manoochehri H, Dama P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: A review study. Cancer Gene Therapy. 2022; 29(8–9): 1080–1096. doi: 10.1038/s41417-021-00418-1
  3. CAR T-Cell Therapy Approved for Children, Young Adults with Leukemia-NCI. Available online: https://www.cancer.gov/news-events/cancer-currents-blog/2017/tisagenlecleucel-fda-childhood-leukemia (accessed on 28 May 2024).
  4. Shah NN, Lee DW, Yates B, et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. Journal of Clinical Oncology. 2021; 39(15): 1650–1659. doi: 10.1200/jco.20.02262
  5. Cobb DA, Lee DW. Cytokine Release Syndrome Biology and Management. The Cancer Journal. 2021; 27(2): 119–125. doi: 10.1097/ppo.0000000000000515
  6. Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Human Vaccines & Immunotherapeutics. 2017; 13(9): 1972–1988. doi: 10.1080/21645515.2017.1316909
  7. Lin E, Lin CH, Lane HY. Relevant Applications of Generative Adversarial Networks in Drug Design and Discovery: Molecular De Novo Design, Dimensionality Reduction, and De Novo Peptide and Protein Design. Molecules. 2020; 25(14): 3250. doi: 10.3390/molecules25143250
  8. Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F, et al. Strategies for Dodging the Obstacles in CAR-T Cell Therapy. Frontiers in Oncology. 2021; 11. doi: 10.3389/fonc.2021.627549
  9. Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine. 2020; 382(6): 545–553. doi: 10.1056/nejmoa1910607
  10. Qin YT, Li YP, He XW, et al. Biomaterials promote in vivo generation and immunotherapy of CAR-T cells. Frontiers in Immunology. 2023; 14. doi: 10.3389/fimmu.2023.1165576
  11. Mi J, Ye Q, Min Y. Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors. Frontiers in Immunology. 2022; 13. doi: 10.3389/fimmu.2022.849759
  12. Marofi F, Motavalli R, Safonov VA, et al. CAR-T cells in solid tumors: challenges and opportunities. Stem Cell Research & Therapy. 2021; 12(1). doi: 10.1186/s13287-020-02128-1
  13. Guzman G, Reed MR, Bielamowicz K, et al. CAR-T Therapies in Solid Tumors: Opportunities and Challenges. Current Oncology Reports. 2023; 25(5): 479–489. doi: 10.1007/s11912-023-01380-x
  14. CAR T Cells: Second-Line Treatment Option for NHL-NCI. Available online: https://www.cancer.gov/news-events/cancer-currents-blog/2022/nhl-car-t-cells-belinda-transform-zuma7 (accessed on 28 May 2024).